Abstract:Pancreatic lipase (PL), a crucial enzyme responsible for hydrolysis of dietary lipids, has been validated as a key therapeutic target to prevent and treat obesity-associated metabolic disorders. Herein, we report the design, synthesis and biological evaluation of a series of chalcone-like compounds as potent and reversible PL inhibitors. Following two rounds of structural modifications at both A and B rings of a chalcone-like skeleton, structure-PL inhibition relationships of the chalcone-like compounds were studied, while the key substituents that would be beneficial for PL inhibition were revealed. Among all tested chalcone-like compounds, compound B13 (a novel chalcone-like compound bearing two long carbon chains) displayed the most potent PL inhibition activity, with an IC50 value of 0.33 μM. Inhibition kinetic analyses demonstrated that B13 could potently inhibit PL-mediated 4-MUO hydrolysis in a mixed inhibition manner, with the Ki value of 0.12 μM. Molecular docking simulations suggested that B13 could tightly bind on PL at both the catalytic site and a non-catalytic site that was located on the surface of PL, which was consistent with the mixed inhibition mode of this agent. In addition, B13 displayed excellent stability in artificial gastrointestinal fluids and good metabolic stability in human liver preparations. Collectively, our findings suggested that chalcone-like compounds were good choices for design and development of orally administrated PL inhibitors, while B13 could be served as a promising lead compound to develop novel anti-obesity agents via targeting on PL.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop more effective oral pancreatic lipase (PL) inhibitors for the prevention and treatment of obesity - related metabolic disorders. Specifically, the authors focus on the following points: 1. **Background problems**: - Obesity has become a major health threat in modern society and is closely related to a variety of metabolic diseases (such as insulin resistance, diabetes, cardiovascular diseases and cancer). - Pancreatic lipase (PL) is a key enzyme responsible for hydrolyzing dietary triglycerides into fatty acids and glycerol in the gastrointestinal tract, and is therefore considered a key target for the prevention and treatment of obesity and its related diseases. - The current FDA - approved drug Orlistat, although effective, has adverse gastrointestinal side effects (such as abdominal distension, diarrhea, etc.), which limit its long - term use, especially in vulnerable populations such as the elderly and children. 2. **Research objectives**: - Design, synthesize and evaluate a series of new chalcone - like compounds as highly efficient and reversible pancreatic lipase inhibitors. - Optimize the activities of these compounds through structural modification, reveal their structure - activity relationships (SAR), and explore their inhibitory mechanisms. - Look for candidate compounds with high activity, low toxicity and good metabolic stability as lead compounds for the development of new anti - obesity drugs. 3. **Specific scientific problems**: - **Chemical stability**: Natural chalcone compounds are unstable under light and physiological conditions due to their α,β - unsaturated ketone structures, and are easily metabolized or degraded. Therefore, analogues with more stable chemical properties need to be designed. - **Activity optimization**: Systematically modify the substituents on ring A and ring B to find the key structural features that can significantly enhance PL inhibitory activity. - **Inhibitory mechanism**: Verify the inhibitory pattern (competitive, non - competitive or mixed) of the best compound (such as B13) on PL, and reveal its binding sites and key interactions through molecular docking simulations. - **In vivo stability**: Evaluate the stability of the compounds in artificial gastrointestinal fluids and human liver microsomes to ensure their potential as oral drugs. 4. **Core achievements**: - Synthesized and tested 30 new chalcone - like compounds, and found that compound B13 has the strongest PL inhibitory activity (IC50 = 0.33 μM). - Inhibition kinetic analysis shows that B13 acts on PL in a mixed - type inhibition mode, with a Ki value of 0.12 μM. - Molecular docking simulations show that B13 can bind simultaneously to the catalytic site of PL and a non - catalytic site on the enzyme surface, which is consistent with its mixed - type inhibition mechanism. - B13 shows good stability in artificial gastrointestinal fluids and human liver microsomes, indicating its potential for development as an oral anti - obesity drug. In summary, this paper aims to overcome the shortcomings of existing PL inhibitors by designing and optimizing chalcone - like compounds, and to provide new directions and candidate compounds for the development of a new generation of anti - obesity drugs.

Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors

Efficient Screening of Pancreatic Lipase Inhibitors from Rheum Palmatum by Affinity Ultrafiltration-High-performance Liquid Chromatography Combined with High-Resolution Inhibition Profiling

Design, synthesis and biological evaluation of salicylanilides as novel allosteric inhibitors of human pancreatic lipase

Design, Synthesis, and Structure‐Activity Relationship Study of Pyrazolones as Potent Inhibitors of Pancreatic Lipase

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Discovery of novel chromone and acrylate‐based pancreatic lipase inhibitors: Molecular modelling, synthesis, and in vitro evaluation for the treatment of obesity

Molecular modelling, synthesis and in vitro evaluation of quinazolinone hybrid analogues as potential pancreatic lipase inhibitors

Exploring flavonoid derivatives as potential pancreatic lipase inhibitors for obesity management: An in silico and in vitro study

Discovery of lignans and curcuminoids as the effective inhibitors of pancreatic lipase: structure-activity relationship and inhibitory mechanism

Construction of a QSAR Model Based on Flavonoids and Screening of Natural Pancreatic Lipase Inhibitors

Synthesis and Characterization of Short α and β-Mixed Peptides with Excellent Anti-Lipase Activities

Discovery of natural anthraquinones as potent inhibitors against pancreatic lipase: structure-activity relationships and inhibitory mechanism

Pancreatic lipase immobilization on cellulose filter paper for inhibitors screening and network pharmacology study of anti-obesity mechanism

Characterization of the synergistic inhibitory effect of cyanidin-3-O-glucoside and catechin on pancreatic lipase

Efficient screening of pancreatic lipase inhibitors from cod meat hydrolysate through ligand fishing strategy

[On a case of intermittent supraventricular tachycardia].

Biaryl carboxamide‐based peptidomimetics analogs as potential pancreatic lipase inhibitors for treating obesity

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists